2023

Mussai, F. et al. (2023) A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: results from the LI-1 trial. British Journal of Haematology, 200(5), pp. 573-578. (doi: 10.1111/bjh.18560) (PMID:36413792)

Othus, M. et al. (2023) Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. Leukemia and Lymphoma, 64(1), pp. 250-252. (doi: 10.1080/10428194.2022.2131416) (PMID:36226777)

2022

Tazi, Y. et al. (2022) Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications, 13, 4622. (doi: 10.1038/s41467-022-32103-8) (PMID:35941135)

Russell, N. H., Hills, R. K., Kjeldsen, L., Clark, R. E., Ali, S., Cahalin, P., Thomas, I. F. and Burnett, A. K. (2022) A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: results from the UK NCRI AML17 trial. British Journal of Haematology, 198(3), pp. 528-534. (doi: 10.1111/bjh.18195) (PMID:35388465)

Russell, N., Hills, R., Kjeldsen, L., Dennis, M. and Burnett, A. (2022) Treatment intensification with FLAG‐Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long‐term follow up of the MRC AML15 trial. British Journal of Haematology, 196(6), pp. 1344-1347. (doi: 10.1111/bjh.17974) (PMID:34904225)

2021

Dennis, M. et al. (2021) Randomised evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances, 5(24), pp. 5621-5625. (doi: 10.1182/bloodadvances.2021005038) (PMID:34597366) (PMCID:PMC8714727)

Lin, W.-Y. et al. (2021) Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 12, 6233. (doi: 10.1038/s41467-021-26551-x) (PMID:34716350)

Articles

Mussai, F. et al. (2023) A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: results from the LI-1 trial. British Journal of Haematology, 200(5), pp. 573-578. (doi: 10.1111/bjh.18560) (PMID:36413792)

Othus, M. et al. (2023) Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. Leukemia and Lymphoma, 64(1), pp. 250-252. (doi: 10.1080/10428194.2022.2131416) (PMID:36226777)

Tazi, Y. et al. (2022) Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications, 13, 4622. (doi: 10.1038/s41467-022-32103-8) (PMID:35941135)

Russell, N. H., Hills, R. K., Kjeldsen, L., Clark, R. E., Ali, S., Cahalin, P., Thomas, I. F. and Burnett, A. K. (2022) A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: results from the UK NCRI AML17 trial. British Journal of Haematology, 198(3), pp. 528-534. (doi: 10.1111/bjh.18195) (PMID:35388465)

Russell, N., Hills, R., Kjeldsen, L., Dennis, M. and Burnett, A. (2022) Treatment intensification with FLAG‐Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long‐term follow up of the MRC AML15 trial. British Journal of Haematology, 196(6), pp. 1344-1347. (doi: 10.1111/bjh.17974) (PMID:34904225)

Dennis, M. et al. (2021) Randomised evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances, 5(24), pp. 5621-5625. (doi: 10.1182/bloodadvances.2021005038) (PMID:34597366) (PMCID:PMC8714727)

Lin, W.-Y. et al. (2021) Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 12, 6233. (doi: 10.1038/s41467-021-26551-x) (PMID:34716350)